Published in Med Dosw Mikrobiol on January 01, 1965
A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol (1995) 3.35
[The taxonomic problem of Clostridium sordellii and Clostridium bifermentans]. Med Dosw Mikrobiol (1966) 1.72
Indigenous hepatitis E virus infection of a plasma donor in Germany. Vox Sang (2009) 1.60
Recombination in Tula hantavirus evolution: analysis of genetic lineages from Slovakia. J Virol (1999) 1.54
Dobrava hantavirus causes hemorrhagic fever with renal syndrome in central Europe and is carried by two different Apodemus mice species. J Med Virol (2001) 1.42
Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. Gut (2009) 1.40
Seroprevalence of hantavirus antibodies in Germany as determined by a new recombinant enzyme immunoassay. Eur J Clin Microbiol Infect Dis (1995) 1.28
Milk protein-derived peptide inhibitors of angiotensin-I-converting enzyme. Br J Nutr (2000) 1.22
Type, prevalence, and significance of core promoter/enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease. J Virol (1996) 1.21
Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. Hepatology (1997) 1.20
Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus. J Virol (1997) 1.17
Core particles of hepatitis B virus as carrier for foreign epitopes. Adv Virus Res (1998) 1.17
Frequent and rapid emergence of mutated pre-C sequences in HBV from e-antigen positive carriers who seroconvert to anti-HBe during interferon treatment. Virology (1992) 1.15
Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998. Eur J Epidemiol (2001) 1.14
Short report: simultaneous occurrence of Dobrava, Puumala, and Tula Hantaviruses in Slovakia. Am J Trop Med Hyg (1999) 1.11
Botulinum antitoxins and antibacterial IgM and IgG antibodies in sera of persons immunized with botulinum polytoxoid combined with cholera vaccine. I. Response to botulinum toxoid. Arch Immunol Ther Exp (Warsz) (1976) 1.09
Human cytomegalovirus (HCMV) encephalitis in an immunocompetent young person and diagnostic reliability of HCMV DNA PCR using cerebrospinal fluid of nonimmunosuppressed patients. J Clin Microbiol (1998) 1.05
Clinical characterization of Dobrava hantavirus infections in Germany. Clin Nephrol (2001) 1.04
Genetic characterization of a new hantavirus detected in Microtus arvalis from Slovakia. Virus Genes (1995) 0.95
Accumulation and persistence of hepatitis B virus core gene deletion mutants in renal transplant patients are associated with end-stage liver disease. Hepatology (1996) 0.94
Heterogeneity of hepatitis B virus C-gene sequences: implications for amplification and sequencing. J Hepatol (1993) 0.94
Identification of a novel angiotensin-I-converting enzyme inhibitory peptide corresponding to a tryptic fragment of bovine beta-lactoglobulin. FEBS Lett (1997) 0.94
Life-threatening Dobrava hantavirus infection with unusually extended pulmonary involvement. Clin Nephrol (2004) 0.93
Bioactive peptides derived from milk proteins. Structural, physiological and analytical aspects. Nahrung (1995) 0.93
Nucleosides and nucleotides: natural bioactive substances in milk and colostrum. Br J Nutr (2000) 0.91
Mapping of immunodominant B-cell epitopes and the human serum albumin-binding site in natural hepatitis B virus surface antigen of defined genosubtype. J Gen Virol (2000) 0.90
Detection of human hantavirus infections in Lithuania. Infection (2005) 0.90
Stimulation of human peripheral blood lymphocytes by bioactive peptides derived from bovine milk proteins. FEBS Lett (1996) 0.90
Chimaeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model. Vaccine (1998) 0.90
[Prevalence of hantavirus infections in Germany]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2004) 0.90
Coding strategy of the S and M genomic segments of a hantavirus representing a new subtype of the Puumala serotype. Arch Virol (1995) 0.88
Comparative inhibition of hepatitis B virus DNA polymerase and cellular DNA polymerases by triphosphates of sugar-modified 5-methyldeoxycytidines and of other nucleoside analogs. Antimicrob Agents Chemother (1991) 0.88
Mapping of B-cell epitopes in the nucleocapsid protein of Puumala hantavirus. Viral Immunol (2002) 0.88
Rational use of diagnostic tools in hepatitis C. J Hepatol (1996) 0.87
Lactokinins: whey protein-derived ACE inhibitory peptides. Nahrung (1999) 0.86
HBV core particles allow the insertion and surface exposure of the entire potentially protective region of Puumala hantavirus nucleocapsid protein. Biol Chem (1999) 0.86
New chimaeric hepatitis B virus core particles carrying hantavirus (serotype Puumala) epitopes: immunogenicity and protection against virus challenge. J Biotechnol (1999) 0.86
Transmission of GBV-C/HGV from drug-addicted mothers to their babies. J Hepatol (1997) 0.85
Hepatitis B virus genomes from long-term immunosuppressed virus carriers are modified by specific mutations in several regions. J Gen Virol (1999) 0.85
Analysis of hepatitis B virus populations in an interferon-alpha-treated patient reveals predominant mutations in the C-gene and changing e-antigenicity. Virology (1998) 0.85
Immunodominant B-cell domains of hepatitis C virus envelope proteins E1 and E2 identified during early and late time points of infection. J Hepatol (1999) 0.83
Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1. Virology (1998) 0.83
Caseinophosphopeptides and their cell modulating potential. Biofactors (2004) 0.82
Treatment of chronic hepatitis B with interferon alfa-2b. J Hepatol (1990) 0.82
Primary hepatic or splenic diffuse large B-cell lymphoma and hepatitis C virus infection: a non-fortuitous association? Ann Hematol (2000) 0.82
Study on the immunological heterogeneity of Clostridium botulinum B type toxin. Arch Immunol Ther Exp (Warsz) (1979) 0.82
Chemical characterization and opioid activity of an exorphin isolated from in vivo digests of casein. FEBS Lett (1986) 0.82
Automated bed to aid pulmonary drainage and prevent decubitus ulcers. Med Biol Eng (1975) 0.82
First molecular evidence for Puumala hantavirus in Slovakia. Virus Genes (2001) 0.81
Puumala (PUU) hantavirus strain differences and insertion positions in the hepatitis B virus core antigen influence B-cell immunogenicity and protective potential of core-derived particles. Virology (2000) 0.81
[Prevalence of antibodies to hepatitis A, hepatitis B and hepatitis C viruses in the German population]. Gesundheitswesen (1999) 0.80
DNA vaccination of mice with a plasmid encoding Puumala hantavirus nucleocapsid protein mimics the B-cell response induced by virus infection. J Biotechnol (2001) 0.80
Expression, assembly competence and antigenic properties of hepatitis B virus core gene deletion variants from infected liver cells. J Gen Virol (1999) 0.80
Leg load warning system for the orthopaedically handicapped. Med Biol Eng (1974) 0.80
Sensory ataxia in myelopathy with chronic hepatitis C virus infection. Neurology (2002) 0.80
Characterization of potential insertion sites in the core antigen of hepatitis B virus by the use of a short-sized model epitope. Intervirology (1999) 0.79
Synthetic peptides corresponding to alpha-lactalbumin and beta-lactoglobulin sequences with angiotensin-I-converting enzyme inhibitory activity. Biol Chem Hoppe Seyler (1996) 0.79
Mosaic hepatitis B virus core particles allow insertion of extended foreign protein segments. J Gen Virol (1997) 0.78
Warning device for the prevention of ischaemic ulcers in quadriplegics. Med Biol Eng (1976) 0.77
[Studies on Clostridium botulinum type F. I. Properties of selected cultures of the Langeland strain]. Med Dosw Mikrobiol (1968) 0.77
Immunological response to Clostridium botulinum toxin. J Clin Microbiol (1988) 0.77
Interaction of wild-type and naturally occurring deleted variants of hepatitis B virus core polypeptides leads to formation of mosaic particles. FEBS Lett (2000) 0.77
[Treatment of chronic hepatitis B with interferon alpha-2b]. Gastroenterol J (1990) 0.76
Post-translational phosphorylation affects the IgE binding capacity of caseins. FEBS Lett (2000) 0.76
Low dose alpha interferon treatment in chronic hepatitis B virus infection. Gut (1993) 0.76
A new variant of progressive encephalomyelitis with rigidity associated with cerebellar ataxia and dementia: correlation of MRI and histopathological changes. A case report. Neurol Res (1997) 0.76
Botulinum antitoxins and antibacterial IgM and IgG antibodies in sera of persons immunized with botulinum polytoxoid combined with cholera vaccine. II. Response to cholera vaccine. Arch Immunol Ther Exp (Warsz) (1976) 0.76
Parvovirus B19 infection associated with unilateral cervical lymphadenopathy, apoptotic sinus histiocytosis, and prolonged fatigue. J Clin Pathol (2005) 0.76
[Studies on Clostridium botulinum type E. VI. Binding power of the type E of botulinum toxin]. Med Dosw Mikrobiol (1965) 0.75
[Effect of whole-body x-ray irradiation on the formation of immunity in mice immunized with tetanus anatoxin. I. Primary immunity to tetanus toxin]. Med Dosw Mikrobiol (1972) 0.75
[Some problems concerning the sterility testing of biological preparations]. Med Dosw Mikrobiol (1967) 0.75
[Study of soluble antigens of type E Clostridium botulinum by gel diffusion]. Med Dosw Mikrobiol (1965) 0.75
[Recommendations for the detection, prevention and control of viral hepatitis]. Z Arztl Fortbild (Jena) (1990) 0.75
[Immunogenicity and antigenic properties of staphylococcal toxoid and vaccine in laboratory animals. II. Staphylococcal vaccine]. Med Dosw Mikrobiol (1973) 0.75
[Bacteroides fragilis and its role in infections]. Pol Tyg Lek (1978) 0.75
Semi-preparative isolation of phosphopeptides derived from bovine casein and dephosphorylation of casein phosphopeptides. Nahrung (1996) 0.75
[Processing of preparations for the determination of immunogenic activity of adsorbed diphtheria and tetanus toxoids]. Med Dosw Mikrobiol (1970) 0.75
[Immunogenecity and antigenic properties of staphylococcal toxoid and vaccine in laboratory animals. I. Staphylococcal toxoid]. Med Dosw Mikrobiol (1973) 0.75
[An evaluation of the efficacy of the accelerated immunization method in guinea pigs immunized with tetanus toxoid]. Med Dosw Mikrobiol (1970) 0.75
[Pathogenic role of various pleomorphic gram-negative bacteria]. Przegl Epidemiol (1976) 0.75
[An attempt to isolate beta antigen (DN-ase) from Cl. septicum culture filtrates]. Med Dosw Mikrobiol (1966) 0.75
[Gram-negative, rod-like, asporogenic anaerobes and diseases caused by them]. Pol Tyg Lek (1977) 0.75
[Effect of whole-body x-ray irradiation on the formation of immunity in mice immunized with tetanus toxoid. II. Secondary immunity to tetanus toxin]. Med Dosw Mikrobiol (1972) 0.75
Thermal response of paraplegic skin to the application of localized pressure. Arch Phys Med Rehabil (1981) 0.75
[Immunoenzyme assay for the demonstration of antibodies against hepatitis B surface antigen (anti-HBs)]. Z Med Lab Diagn (1986) 0.75
[Immunogenicity of antirabies vaccines]. Med Dosw Mikrobiol (1972) 0.75
Giving. West J Med (1991) 0.75
[Hepatitis B screening in pregnant patients and their children. A Greifswald perinatology-pediatric study. II. Pediatric findings]. Zentralbl Gynakol (1989) 0.75
[Synthesis of IgM and IgG antibodies in x-ray irradiated mice and immunized with tetanus toxoid]. Med Dosw Mikrobiol (1972) 0.75
Short communication: bovine kappa-casein variants result in different angiotensin I converting enzyme (ACE) inhibitory peptides. J Dairy Sci (2009) 0.75
[The relation of B- and non-A, non-B hepatitis virus--hepatitis B virus (HBV) DNA hybridization studies of the sera in non-A, non-B hepatitis]. Z Gesamte Inn Med (1989) 0.75
[The association of hepatitis-B-virus infection and hepatocellular carcinoma]. Z Arztl Fortbild (Jena) (1991) 0.75
[Treatment of chronic hepatitis B with interferon alpha-2b]. Dtsch Med Wochenschr (1990) 0.75
Comparison of direct and indirect two-site binding enzyme immunoassay. Clin Chim Acta (1982) 0.75
[Diseases caused by some Gram-negative pleomorphic microaerophilic organisms and absolute anaerobes]. Pol Tyg Lek (1976) 0.75
[Risk of hepatitis B in endoscopy personnel]. Dtsch Z Verdau Stoffwechselkr (1981) 0.75
[Hepatitis and imported infectious diseases. A. Hepatitis. 1. Virologic findings in acute hepatitis]. Z Gesamte Inn Med (1983) 0.75
Fluorographic determination of 3H-labeled hepatitis B virus DNA and other viral DNAs. Z Med Lab Diagn (1986) 0.75
Comparison of three different recombinant hepatitis B virus core particles expressed in Escherichia coli. Arch Virol (1994) 0.75
Structure and selection of hepatitis B virus variants during the natural course of infection and interferon therapy. Princess Takamatsu Symp (1995) 0.75